AIPLA tells US Congress: We cannot support Innovation Act

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

AIPLA tells US Congress: We cannot support Innovation Act

AIPLA has written to Congress saying it cannot support the Innovation Act because of objections to several provisions within the bill and the speed with which the legislation has moved forward.

The association, which represents about 15,000 lawyers and other IP professionals, urged Congress to “take a balanced approach that also continues to encourage innovation” when considering the bill, otherwise known as H.R. 3309.

In the letter, sent yesterday, AIPLA made suggestions including:


· Ensure that Section 3 and Section 6 do not “interfere with the traditional discretion of the courts by avoiding inflexible legislatively mandated rules.” Section 3 would require more transparency in claims and oblige patent holders making claims not “reasonably justified in law and fact” to pay the other party’s attorneys fees.

· Retain Section 9(c), which would require the USPTO to use the same claim construction standard in inter partes and post-grant review as is used by district courts. At present, the USPTO uses the “broadest reasonable interpretation” standard, which is designed to prevent overly broad claims and is less advantageous to patent holders than the standard used by the district courts.

· Rewrite Section 5, which allows courts to stay suits against customers when there is parallel litigation against a manufacturer, so that is “not so overbroad that genuine infringers receive the protection intended for the innocent.”

· Remove Section 9(a), which strikes Section 145 of the AIA. Section 145 allows patent applicants to challenge the USPTO’s refusal of a patent application in district court after appealing to the USPTO’s Patent Trial and Appeal Board (PTAB). (Other potential recourses for applicants include appealing directly to the Federal Circuit under Section 141 or filing a continuation application.)

· Retain Section 9(b), which would strike “or could reasonably have raised” from the estoppel provisions of 35 USC Section 325. AIPLA claims this would encourage those challenging patents to do so in the early stages of the patent term, “when reliance, commercialisation and related investment are likely at their minimum.”

· Give further consideration to other provisions, such as Section 9(d) on double patenting, Section 9(f) on patent term adjustment, and Section 9(g) on clarification of jurisdiction.

AIPLA also said it was disappointed the bill did not “secure full funding” for the USPTO. The organisation has been campaigning to have the USPTO exempted from budget sequestration.

more from across site and SHARED ros bottom lb

More from across our site

Former Hoyng Rokh Moneiger partner Laura Alonso, who brought her team to ECIJA in March, discusses plans to expand further and why ECIJA’s ‘IP DNA’ is helping broaden her work
Amita Haylock discusses building an integrated Asia practice as clients increasingly demand that firms combine IP, technology and data expertise
François Pochart, Grégoire Desrousseaux and Lionel Martin, long-standing figures in the firm’s patent litigation team, are set to help launch a Paris-based litigation offering
The Unitary Patent has passed 100,000 registrations, but new data raises the question of whether 30% uptake is a ceiling or a staging post for further growth, say Michael Nielsen and Darren Smyth of EIP and Andrew Samm at Patently
The new generation of in-house IP leaders want commercial judgment, accessibility and flexibility, with AI raising expectations around both fees and delivery
The firm launched a San Diego office earlier this month, but California investment and expansion is far from complete
The industry’s response to AI requires an unfamiliar ingredient as firms battle to shape their futures
The firm is looking beyond replacing recently departed talent, betting instead on senior leaders to strengthen and expand its patent litigation platform
Olga Partington, director in Sterne Kessler’s biotechnology and chemical practice group, shares why a patent's vulnerability peaks when it is young, rather than when it is most valuable, under the PTAB's new framework
IP experts gathered in San Francisco last week to discuss the changing global SEP landscape and new licensing models for AI infrastructure
Gift this article